Clinical effects of everolimus in the subjects with tuberous sclerosis
Latest Information Update: 27 Sep 2022
At a glance
- Drugs Everolimus (Primary)
- Indications Tuberous sclerosis
- Focus Therapeutic Use
- 18 Sep 2022 Planned number of patients changed from 45 to 20.
- 27 Sep 2021 Planned End Date changed to 10 Apr 2026.
- 27 Sep 2021 Timepoint of primary endpoint has been changed from September, 2023 to September, 2026